Pharmaphorum
Drug research is plagued with extreme costs and high failure rates. Here’s how genetic data could transform how we develop medications
Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate ...
$2.8 million Zynteglo gene therapy: Bluebird sets price on one-time beta-thalassemia treatment replacing red blood cell transfusions
Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA ...